Sarepta's next chapter depends on siRNA data, not Elevidys

The technology

Sarepta has two working platforms and is betting on a third. The exon-skipping drugs Exondys 51, Vyondys 53 and Amondys 45 are antisense drugs designed to raise dystrophin levels in muscle, and ESSENCE showed dystrophin rose on treatment. They sell about $230 million a quarter. Elevidys is an AAV gene therapy that delivers micro-dystrophin. Since November 2025 it carries a boxed warning for acute liver failure and is limited to ambulatory patients aged 4 and older.

The new bet is siRNA. Sarepta licensed an αvβ6 integrin-targeted delivery system from Arrowhead Pharmaceuticals that carries siRNA into skeletal muscle. First single-dose data in FSHD1 (SRP-1001) and DM1 (SRP-1003) showed drug levels in muscle rising with dose, lower target levels and mostly mild to moderate side effects, per RARE Daily. A Huntington's program, SRP-1005, has started dosing in a phase 1 study.

The odds

The siRNA programs sit in phase 1/2. Published data put the chance that a phase 1 drug reaches approval at 7.9% overall and 17.0% in rare disease. Early target knockdown in muscle helps, but single-dose biomarker data say little about function. The repeat-dose cohorts are the first real test, and Sarepta has not yet said which functional measures it will use to judge them.

The near-term regulatory test is ESSENCE. That study missed its primary endpoint of 4-step ascend velocity, with a difference of 0.06 steps per second (P = .309), while dystrophin rose. The FDA will rule on traditional approval for Vyondys 53 and Amondys 45 by Feb. 28, 2027. The 90.6% base rate for filings reaching approval assumes positive confirmatory data, so it is a poor guide here.

The money

Sarepta had $945.0 million in cash, equivalents, restricted cash and investments on June 30, 2026, and its 10-Q lists $847.6 million in convertible notes due in 2027 and 2030. The company says resources cover the operating plan for at least 12 months. Product revenue guidance for 2026 is $1.2 billion to $1.3 billion, and combined non-GAAP R&D and SG&A guidance is $800 million to $850 million.

The Arrowhead deal is the large fixed cost. Sarepta owes $50 million a year in license fees over five years and up to $10.3 billion in milestones, and it paid a $200 million DM1 milestone in the first half of 2026, per the 10-Q.

The risks

Elevidys safety is the first risk. A new liver or cardiac event could shrink the label again, and a path back to non-ambulatory patients depends on sirolimus data due in the first quarter of 2027. The second is the exon-skipping franchise: an adverse FDA ruling would hit the drugs that now earn more than twice what Elevidys does, while Dyne Therapeutics' exon 51 candidate has a Jan. 21, 2027 decision date. The third is siRNA execution, where multiple-dose data have not yet been shown.

Our read

Sarepta is a cash-generating rare disease company that has lost its growth story and is trying to buy a new one. The current business can carry the debt and the Arrowhead payments for now. What changes the picture is whether the siRNA platform shows a functional or strong biomarker effect in DM1 and FSHD with repeat dosing. New CEO Michael Severino, who started July 28, will be judged largely on those readouts and on the February FDA decision, both inside his first seven months. If the siRNA data disappoint, the company is left with a shrinking gene therapy and an exon-skipping franchise whose label depends on how the FDA reads a failed study.